DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study

• Authors: Aristotle Bamias , George Fountzilas , Michael Michael , Christos Konstantaras , Eleftheria Vrettou , Efstathios Eleftheriadis , Pavlos Papakostas , Konstantionos Papadimitriou , Nicholas Pavlidis , Nikos Xiros , Maria Bai
• Languages of publication: EN

Abstracts

EN

There is a high risk of relapse after resection of gastric cancer. We studied the prognostic significance of the deleted colorectal cancer (DCC) gene and thymidylate synthase (TS) protein expression after resection of gastric cancer. Protein expression in the primary tumor of 146 patients with serosal and/or lymph node involvement was studied immunohistochemically by using anti-DCC and anti-TS monoclonal antibodies. DCC expression was found in 69.9%, while low TS staining intensity (0+,1+) and focal staining (<25% of tumor cells stained) were found in 44.6% and 33.8%, respectively. Overall survival (OS) was significantly longer in patients with DCC (p=0.014) negative tumors. TS expression was not an independent prognostic factor. Lack of DCC expression was associated with significantly longer cause-specific survival (CSS) (p=0.040) after curative resection. In conclusion, DCC expression is an independent prognostic factor in patients undergoing resection of gastric cancer while TS expression was not associated with the prognosis in our study.

Keywords

EN

DCC; TS; Gastric cancer

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2008
• Volume: 3
• Issue: 1
• Pages: 29-39

Dates

published

1 - 3 - 2008

online

1 - 3 - 2008

Contributors

author

Aristotle Bamias

• Oncology Dept, Ioannina University Hospital, Ioannina, Greece

author

George Fountzilas

• AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

author

Michael Michael

• Histocytopathology Laboratory, Ioannina University Hospital, Ioannina, Greece

author

Christos Konstantaras

• AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

author

Eleftheria Vrettou

• AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

author

Efstathios Eleftheriadis

• Histocytopathology Laboratory for Social Insurance, Thessaloniki, Greece

author

Pavlos Papakostas

• Ippokration Hospital, Athens, Greece

author

Konstantionos Papadimitriou

• Ippokration Hospital, Athens, Greece

author

Nicholas Pavlidis

• Oncology Dept, Ioannina University Hospital, Ioannina, Greece

author

Nikos Xiros

• Evangelismos Hospital, Athens, Greece

author

Maria Bai

• Histocytopathology Laboratory, Ioannina University Hospital, Ioannina, Greece

References

• [1] Alexander H.R., Kelsen D.P., Tepper J.E., Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA, (Eds.) Cancer. Principles and Practice of Oncology, Philadelphia, Lippincot-Raven Publishers, 1997, 1021–1053
• [2] Fuchs C.S., Mayer R.J., Gastric carcinoma., N. Engl. J. Med., 1995, 333, 32–41 http://dx.doi.org/10.1056/NEJM199507063330107[Crossref]
• [3] Kelsen D.P., Adjuvant and neoadjuvant therapy for gastric cancer., Semin. Oncol., 1996, 23, 379–389
• [4] Cho K.R., Fearon E.R., DCC: Linking tumor suppressor genes and altered cell surface interactions in cancer?, Eur. J. Cancer., 1995, 31A, 1055–1060 http://dx.doi.org/10.1016/0959-8049(95)00128-6[Crossref]
• [5] Uchino S., Tsuda H., Noguchi M., Yokota J., Terada M., Saito T., et al., Frequent loss of heterozygosity at the DCC locus in gastric cancer., Cancer. Res., 1992, 52, 3099–3102
• [6] Fang D.C., Jass J.R., Wang D.X., Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer., J. Clin. Pathol., 1998, 51, 593–596 http://dx.doi.org/10.1136/jcp.51.8.593[Crossref]
• [7] Cropp C.S., Lidereau R., Campbell G., Champene M.H., Callahan R., Loss of heterozygosity on chromosome 17 and 18 in breast carcinoma: two additional regions identified., Proc. Natl. Acad. Sci. USA, 1990, 87, 7737–7741 http://dx.doi.org/10.1073/pnas.87.19.7737[Crossref]
• [8] Gao X., Honn K.V., Grignon D., Sakr W., Chen Y.Q., Frequent loss of expression and loss of heterozygosity of putative tumor suppressor gene DCC in prostatic carcinomas., Cancer. Res., 1993, 53, 2723–2727
• [9] Peng H.Q., Bailey D., Bronson D., Goss P.D., Hong D., Loss of heterozygosity of tumor suppressor genes in testis cancer., Cancer. Res., 1995, 55, 2871–2875
• [10] Jen J., Kim H., Piantadosi S., Liu Z.F., Levitt R.C., Sistonen P., et al., Allelic loss of chromosome 18q and prognosis in colorectal cancer., N. Engl. J. Med., 1994, 331, 213–221 http://dx.doi.org/10.1056/NEJM199407283310401[Crossref]
• [11] O’Connell M.J, Schaid D.J., Ganju V., Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?, Cancer., 1992, 70, 1732–1739 http://dx.doi.org/10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#[Crossref]
• [12] Watanabe T., Tsung-The W., Catalano P.J., Ueki T., Satriano R., Haller D.G., et al., Molecular predictors of survival after adjuvant chemotherapy for colon cancer., N. Engl. J. Med., 2001, 344, 1196–1206 http://dx.doi.org/10.1056/NEJM200104193441603[Crossref]
• [13] Shibata D., Reale M.A., Lavin P., Silverman M., Fearon E.R., Steele G., et al., The DCC protein and prognosis in colorectal cancer., N. Engl. J. Med., 1996, 335, 1727–1732 http://dx.doi.org/10.1056/NEJM199612053352303[Crossref]
• [14] Sun X.F., Rutten S., Zhang H., Nordenskjold B., Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma., J. Clin. Oncol., 1999, 17, 1745–1750
• [15] Candusso M.E., Luinetti O., Villani L., Alberizzi P., Klersy C., Fiocca R., et al., Loss of heterozygosity at 18q21 region in gastric cancer involves a number of cancer-related genes and correlates with stage and histology, but lacks independent prognostic value., J. Pathol. 2002, 197, 44–50 http://dx.doi.org/10.1002/path.1105[Crossref]
• [16] Bamias A.T., Bai M.C., Agnantis N.J., Michael M.C., Alamanos Y.P., Stefanaki S.V., et al., Prognostic significance of the deleted in colorectal cancer (DCC) gene expression in high risk resected gastric carcinoma., Cancer. Investigation, 2003, 21, 333–340 http://dx.doi.org/10.1081/CNV-120018219[Crossref]
• [17] Pinedo H.M., Peters G.F.J., Fluorouracil: Biochemistry and pharmacology., J. Clin. Oncol., 1988, 6, 1653–1664
• [18] Aschele C., Debernardis D., Casazza S., Antonelli G., Tunesi G., Baldo C., et al., Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to Fluorouracil-based chemotherapy., J. Clin. Oncol., 1999, 17, 1760–1770
• [19] Lenz H.J., Hayashi K., Salonga D., Danenberg K.D., Danenberg P.V., Metzger R., et al., P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival., Clin. Cancer. Res., 1998, 4, 1243–1250
• [20] Boku N., Chin K., Hosokawa K., Ohtsu A., Tajiri H., Yoshida S., et al., Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-Fluorouracil and cis-Platinum., Clin. Cancer. Res., 1998, 4, 1469–1474
• [21] Pestalozzi B.C., Peterson H.F., Gelber R.D., Goldhirsch A., Gusterson B.A., Trihia H., et al., Prognostic importance of thymidylate synthase expression in early breast cancer., J. Clin. Oncol., 1997, 15, 1923–1931
• [22] Edler D., Kressner U., Ragnhammar P., Johnston P.G., Magnusson I., Glimelius B., et al., Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival., Clin. Cancer. Res., 2000, 6, 488–492
• [23] Johnston P.G., Fisher E.R., Rockette H.E., Fisher B., Wolmark N., Drake J.C., et al., The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer., J. Clin. Oncol., 1994, 12, 2640–2647
• [24] Allegra C.J., Parr A.L., Wold L.E., Mahoney M.R., Sargent D.J., Johnston P.G., et al., Investigation of the prognostic and predicitve value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer., J. Clin. Oncol., 2002, 20, 1735–1743 http://dx.doi.org/10.1200/JCO.2002.07.080[Crossref]
• [25] Lenz H.J., Leichman C.G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., et al., Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival., J. Clin. Oncol., 1996, 14, 1176–1182
• [26] Suda Y., Kuwashima Y., Tanaka Y., Uchida K., Akazawa S., Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-Fluoropyrimidines., Anticancer. Res., 1999, 19, 805–810
• [27] Choi J.H., Lim H.Y., Nam D.K., Kim H.S., Cho D.Y., Yi J.W., et al., Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection., Br. J. Cancer., 2001, 84, 186–192 http://dx.doi.org/10.1054/bjoc.2000.1553[Crossref]
• [28] Kuniyashu T., Nakamura T., Tabuchi Y., Kuroda Y., Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody., Cancer., 1998, 83, 1300–1306 http://dx.doi.org/10.1002/(SICI)1097-0142(19981001)83:7<1300::AID-CNCR5>3.0.CO;2-M[Crossref]
• [29] Ishikawa Y., Tetsuro K., Otani Y., Watanabe M., Teramoto T., Kumai K., et al., Thymidylate synthetase and Dihydropyrimidine dehydrogenase levels in gastric cancer., Anticancer. Res., 1999, 19, 5635–5640
• [30] Pestalozzi B.C., McGinn C.J., Kinsella T.J., Increased thymidylate synthase protein levels are associated with proliferation but not cell cycle phase in asynchronous human cancer cells., Br. J. Cancer., 1995, 71, 1151–1157 [Crossref]
• [31] Yonemura Y., Kimura H., Fushida S., Tugawa K., Nakai Y., Kaji M., et al., Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy., Cancer. 1993, 71, 2448–2453 http://dx.doi.org/10.1002/1097-0142(19930415)71:8<2448::AID-CNCR2820710804>3.0.CO;2-V[Crossref]
• [32] Kakeji Y., Maehara Y., Adachi Y., Baba H., Mori M., Furusawa M., et al., Proliferative activity as a prognostic factor in Bormann type 4 gastric carcinoma., Br. J. Cancer., 1994, 69, 749–753 [Crossref]
• [33] Bai M., Vlachoniklis J., Agnantis N.J., Tsanou E., Dimou S., Nicolaides C., et al., Low expression of p27 protein combined with altered p53 and Rb/p16 status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas., Mod. Pathol. 2001, 14(11), 1105–1113 http://dx.doi.org/10.1038/modpathol.3880444
• [34] Armitage P., Berry G., Statistical methods in medical research. Oxford, United Kingdom, Blackwell Scientific Publications, 1994
• [35] Kaplan E., Meier P., Nonparametric estimation from incomplete observations., J. Am. Stat. Assoc., 1958, 53, 457–481 http://dx.doi.org/10.2307/2281868[Crossref]
• [36] Cox D.R., Regression models and life tables., J. R. Stat. Soc. B., 1972, 34, 187–220
• [37] MacDonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction., N. Engl. J. Med., 2001, 345, 725–730 http://dx.doi.org/10.1056/NEJMoa010187[Crossref]
• [38] Sato K., Tamura G., Tsuchiya T., Endoh Y., Usuba O., Kimura W., et al., Frequent loss of expression without sequence mutations of the gene in primary gastric cancer., Br. J. Cancer., 2001, 85(2), 199–203 http://dx.doi.org/10.1054/bjoc.2001.1888[Crossref]
• [39] Johnston P.J., Lenz H.J., Leichman C.G., Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors., Cancer. Res., 1995, 55, 1407–1412
• [40] Edler D., Glimelius B., Hallstrom M., Jacobsen A., Johnston P.G., Magnuson I., et al., Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy., J. Clin. Oncol., 2002, 20, 1721–1728 http://dx.doi.org/10.1200/JCO.2002.07.039[Crossref]
• [41] Schipper D.L., Wagenmans M.J.M., Peters W.H.M., Wagener D.J.T., Significance of cell proliferation measurement in gastric cancer., Eur. J. Cancer., 1998, 34, 781–790 http://dx.doi.org/10.1016/S0959-8049(97)10073-9[Crossref]

Identifiers

DOI

10.2478/s11536-007-0054-y